Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog



1257 Features
Type 2 diabetes as a risk factor for Alzheimer's disease - defective insulin-degrading enzyme as an etiological link?

02 Apr 04

DailyUpdates 2nd April: There is growing evidence that type-2 diabetes is a risk factor for Alzheimer disease. In their April American Journal of Pathology article Brigham and Women's Hospital researchers add further evidence to support defects in insulin-degrading enzyme activity as a potential cause of this phenomenon. This and similar data argues for the development of cross-indication treatments of type-2 diabetes and Alzheimer disease and GSK-3 inhibitors may fit the bill.

GREES publish new recommendations on the clinical development of disease modifying osteoarthritis drugs (DMOADs)

01 Apr 04

DailyUpdates 1st April: Osteoarthritis is the most common form of arthritis and is estimated to affect over 73 million people in the seven major pharmaceutical markets. Disease modifying osteoarthritis drugs (DMOADs) currently represent the ‘holy grail’ in the treatment of osteoarthritis. The Group for the Respect of Ethics and Excellence in Science (GREES) have now published recommendations on the clinical development of DMOADs.

Merck & Co develop new leads for the treatment of bipolar disorder through the development of a new HTS assay of inositol monophosphatase inhibitors

31 Mar 04

DailyUpdates 31st March: Bipolar disorder affects over 2 million people in the US alone. Lithium, which inhibits inositol monophosphatase, has long been a first line mood stabilizer used in the treatment of this condition. Merck & Co have now developed a new cell-based HTS assay to identify novel inositol monophosphatase inhibitors which will hopefully lead to improved treatments of bipolar disorder.

Sulfonylureas vs thiazolidinediones for the prevention of diabetic nephropathy

30 Mar 04

DailyUpdates 30th March: According to WHO, there are some 130 million diagnosed diabetics in the world and the long term consequences of diabetes such as diabetic nephropathy are becoming increasingly frequent and unmet components of diabetes care. Intensive glycemic control prevents or retards microalbuminuria, an early sign of nephropathy in patients with type 2 diabetes and in a recent study Japanese researchers compare two different classes of oral antidiabetic drugs with respect to their e

New data published on KW-7158, a novel treatment of overactive bladder

29 Mar 04

Overactive bladder, a condition associated with a variety of other pathologies affects over 17 million Americans and costs the US over $12 billion per year. Current treatments focus on the muscarinic receptor antagonists such as tolterodine and oxybutanin with further examples from this class expected on the market. Therapeutics from novel pharmacological classes are expected to offer further improvements and in an upcoming edition of the Journal of Pharmacology & Experimental Therapeutics Uni

Naked Ambition

28 Mar 04

The presence of Arthur Dent's in pyjamas throughout the Hitch Hiker's Guide to the Galaxy, in a series of increasingly surreal encounters, acts as a constant reminder to the reader that no matter what
Daniel Judge

All in the name of research

25 Mar 04

Andrew Curl from the ABPI explains more about the industry's ability to innovate and provide world-beating medicines.
Claire Richland

Finding the Next Asian Pharma Sensation

19 Mar 04

Japan has always been considered the technology pioneer of Asia, however, in recent years a number of other countries in this region have placed significant emphasis on industrial and technological performance in order to improve their own world position. One industry that is developing rapidly in the region is the pharmaceutical industry.
Dr Faiz Kermani and Dr Rebecca Gittins

Emerging Drug Discovery Targets: 6th February

13 Feb 04

This edition of "Emerging Drug Discovery Targets" features a potential approach to the treatment of COPD; Ligands' retinoic acid receptor agonist with appetite suppressive and insulin sensitizing properties; the use of HDAC inhibitors for the treatment of rheumatoid arthritis; Tamoxifen as a dual chemopreventative and anti-atherosclerosis treatment; and broad based inhibition of multidrug resistance proteins for improved cancer treatment. As usual we also provide updates on industrial advances a

Pharma NewsBytes: 6th February

13 Feb 04

Pharma NewsBytes selects out what we consider as being some of the most interesting press releases to have appeared on our DailyUpdates tracking service over the past few weeks. Currently featured new items focus on a number of novel approaches to the treatment of cancer including the development of caspase inhibitors; gene therapy approaches to the expression of TNF-alpha; an advanced monoclonal antibody; and a strategy to block XIAP. In addition new therapeutics for the treatment of rheumatoid

The effects of insulin on airway function: repercussions for intra-tracheal insulin delivery and for asthma therapeutics

13 Feb 04

According to WHO, there are some 130 million diagnosed diabetics in the world. The market for diabetes therapeutics is rising. Oral antidiabetic drugs, the leading class of drugs used to treat the disease, accounted for almost 63% of sales during this period, while sales of insulin stand at around 30%. Further increases are inevitable and the market for diabetes medications could exceed $20 billion by 2006. The largest unmet need in the diabetes market is improved delivery of insulin. Currently,

Canada commits to R&D

04 Feb 04

By 2010 Canada aims to become one of the top 5 countries in the world in terms of industrial R&D performance. Its pharmaceutical and biotech sectors, which are already key contributors to the economy, look set to prosper.
Dr Faiz Kermani and Dr Rebecca Gittins

Emerging Molecular Targets to Treat Disorders Affecting Cognitive Function

03 Feb 04

Pharmaceutical Education Associates’ presents a one-of-a-kind forum exploring the most recent and clinically relevant research pertaining to brain targets for the enhancement of cognitive function. Of particular interest will be the effectiveness of new cognition-enhancing drugs in the treatment of neurodegenerative disorders such as Alzheimer’s disease, as well as their potential for the treatment of the cognitive decline associated with normal aging or as a prelude to disease.
Jennifer McGinnis


20 Jan 04

a Bristol based Biochemical Company, says it has invented a new sprayable antibacterial disinfectant agent, to be launched under the name of D-Stroy, that can kill the hospital superbug MRSA and TB.
Daisy Norman

Why Pharmaceutical R&D investment can pay off

19 Jan 04

Obtaining a benefit from pharmaceutical R&D investment requires long-term planning and a consideration of how the commercial and technological environment in which the industry operates might change.
Dr Faiz Kermani

Can Pharma Reign in Spain? – Part 2

12 Jan 04

Spain has a buoyant pharmaceutical market, but it is also a growing centre for pharmaceutical R&D. Industry figures show that there has been a rapid rise in R&D investment in the country since the early 1990s.
Dr Faiz Kermani

Emerging Drug Discovery Targets (18th December 2003)

05 Jan 04

This edition of features new generation oncolytic viruses from Cell Genesys active against colorectal cancer cells; a p38 MAPK inhibitor for the treatment of rheumatoid arthritis from Fujisawa; data describing the anti-angiogenic activity of bisphosphonates in cancer models; a new JAK3 inhibitor from Pfizer for transplant rejection; and an integrin antagonist from Merck for the treatment of osteoporosis. As usual updates on industrial advances and licensing opportunities are provided.

2nd Annual Pediatric Drug Development

02 Jan 04

Pharmaceutical Education Associates' proud to present our 2nd Annual Pediatric Drug Development conference, slated for February 23-24, 2004 in Washington, D.C. Don't miss your chance to hear about the key issues impacting pediatric drug development today! For more information call us at 800-686-2276 visit
Feliz Casanova

Can Pharma Reign in Spain? – Part 3

23 Dec 03

The growth of the pharmaceutical market and an improvement in the conditions for R&D, have led to increased emphasis being placed on Spain by pharmaceutical companies. Measures have also been taken by the Spanish government to directly boost pharmaceutical R&D innovation.
Dr Faiz Kermani

Can Pharma Reign in Spain? Part 1

23 Dec 03

As with most major pharmaceutical markets, patient demand for the latest innovative products has helped drive growth of the Spanish pharmaceutical market.
Dr Faiz Kermani

Which Recruitment Consultancy?

18 Dec 03

Which ever side of the desk you’re on you will be familiar with the principle of the trade-off between the cost of recruitment and the cost of failure to recruit the right person – never more in the spotlight than now.
Nigel Haigh

Janus tyrosine kinase 3 inhibition for the prevention of transplant rejection

18 Dec 03

Transplantation immunotherapy commonly involves the use of azathioprine often combined with low doses of cyclosporine. Increased susceptibility to infection and severe toxicity represent serious adverse effects and a newer molecular target being investigated for the prevention of transplant rejection is Janus tyrosine kinase 3 (Jak3). Jak3 is this months "Target of the Month" from LeadDiscovery's and here they describe Pfizer's efforts to optimize inhibitors of this kinase

Pharma NewsBytes: Selected pharma press releases - Dec 1st-17th

18 Dec 03

Pharma NewsBytes selects out what LeadDiscovery considers as being some of the most interesting press releases to have appeared on their DailyUpdates tracking service over the past few weeks. Currently featured new items focus on development activity in the field of Alzheimer's disease; advances in autoimmune diseases and inflammatory disorders; and news from the 26th Annual San Antonio Breast Cancer Symposium

A gap in the market

18 Dec 03

According to research by market analyst, Datamonitor, pharmaceutical companies drug promotion spends are on an upward spiral.
John Gawley

How to | Cope with Redundancy

16 Dec 03

Redundancy – meaning a position of employment is no longer tenable – is a traumatic experience. It is possibly one of the most devastating events you’ll have to go through in your career but one that is becoming all too frequent across the industry.
Aileen Parlane

Interviews and your personality report

16 Dec 03

Personality test experts People Maps return to offer candidates more invaluable advise about the use of personality profilers and their importance in the job interview process
Martin Gibbons

Best Practices for Medical Science Liaisons

15 Dec 03

This comprehensive one-day training offers MSLs, their managers and those interested in a better understanding of the profession an overview of what the job entails, best practices and realistic ways to incorporate them into your own job. The training will focus on the components of a successful career as a MSL, as opposed to educating on individual therapeutic types.
Jennifer McGinnis

Global Clinical Supplies

15 Dec 03

Increased regulations and review are continually challenging clinical supply operations. In addition, managing diverse resources while ensuring accurate, timely supply of materials is always difficult. Pharmaceutical Education Associates “Global Clinical Supplies” conference will show you the key strategies you’ll need to ensure efficiency and compliance in your global supply operations.
Jennifer McGinnis

Emerging Drug Discovery Targets

21 Nov 03

This edition of "Emerging Drug Discovery Targets" features a potent histone deacetylase inhibitor from Norvartis for the treatment of cancer, two new approaches to metabolic disorders and VEGFR-1 as a target for rheumatoid arthritis. As usual we also provide updates on industrial advances and licensing opportunities.

NVP-LAQ824 a novel histone deacetylase inhibitor

19 Nov 03

The field of histone deacetylation continues to receive considerable interest principally due to the ability of histone deacetylase (HDAC) inhibitors to produce cytostatic activity in cancer, but more recently due to the role that this class has in other indications such as autoimmune disorders. Novartis researchers have now developed a HDAC inhibitor of greater anti-proliferative potency than that of SAHA, and which almost completely blocked the growth of human colon and lung cancer xenografts

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.